Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $100M | $-69M | $-73M | $-56M | -25.5% | 53.9% | 33.7% |
| 2024 | $65M | $-43M | $-55M | $-52M | 22.3% | 442.9% | 24.2% |
| 2023 | $12M | $-34M | $-44M | $-33M | 21.7% | 6601.1% | -31.9% |
| 2022 | $0M | $-63M | $-65M | $-61M | 38.1% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0.18 | 12 | 65.12 | 100.25 |
| Operating Revenue | 0.18 | 12 | 65.12 | 100.25 |
| Cost Of Revenue | - | 5.69 | 29.24 | 44.71 |
| Gross Profit | 0.18 | 6.31 | 35.89 | 55.54 |
| Operating Expense | 66.02 | 42.16 | 81.14 | 127.22 |
| Research And Development | 31.43 | 17.94 | 26.18 | 34.79 |
| Selling General And Administration | 34.60 | 24.22 | 54.96 | 92.43 |
| Total Expenses | 66.02 | 47.84 | 110.38 | 171.93 |
| Operating Income | -65.84 | -35.85 | -45.25 | -71.68 |
| Total Operating Income As Reported | -65.84 | -35.85 | -45.25 | -71.68 |
| EBITDA | -62.65 | -33.76 | -42.97 | -68.81 |
| Normalized EBITDA | -63.56 | -23.80 | -29.56 | -56.36 |
| EBIT | -64.74 | -35.85 | -45.25 | -71.68 |
| Interest Income | 0.20 | 1.78 | 3.91 | 10.93 |
| Interest Expense | 0.01 | 0.07 | - | - |
| Net Interest Income | 0.18 | 1.78 | 3.91 | 10.93 |
| Other Non Operating Income Expenses | - | -0.07 | 0 | 0 |
| Other Income Expense | 0.91 | -10.03 | -13.41 | -12.45 |
| Interest Income Non Operating | 0.20 | 1.78 | 3.91 | 10.93 |
| Interest Expense Non Operating | 0.01 | 0.07 | - | - |
| Net Non Operating Interest Income Expense | 0.18 | 1.78 | 3.91 | 10.93 |
| Pretax Income | -64.75 | -44.10 | -54.76 | -73.20 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | -64.75 | -44.10 | -54.76 | -73.20 |
| Net Income From Continuing And Discontinued Operation | -64.75 | -44.10 | -54.76 | -73.20 |
| Net Income From Continuing Operation Net Minority Interest | -64.75 | -44.10 | -54.76 | -73.20 |
| Net Income | -64.75 | -44.10 | -54.76 | -73.20 |
| Net Income Common Stockholders | -64.75 | -44.10 | -54.76 | -73.20 |
| Net Income Including Noncontrolling Interests | -64.75 | -44.10 | -54.76 | -73.20 |
| Normalized Income | -65.66 | -34.14 | -41.34 | -60.75 |
| Diluted NI Availto Com Stockholders | -64.75 | -44.10 | -54.76 | -73.20 |
| Basic Average Shares | 30.50 | 30.50 | 42.86 | 40.53 |
| Diluted Average Shares | 30.50 | 30.50 | 42.86 | 40.53 |
| Reconciled Depreciation | 2.09 | 2.09 | 2.28 | 2.88 |
| Reconciled Cost Of Revenue | - | 5.69 | 29.24 | 44.71 |
| Total Unusual Items | 0.91 | -9.96 | -13.41 | -12.45 |
| Total Unusual Items Excluding Goodwill | 0.91 | -9.96 | -13.41 | -12.45 |
| Gain On Sale Of Security | 0.91 | -9.96 | -13.41 | -12.45 |
| General And Administrative Expense | 26.15 | 12.22 | 17.87 | 31.02 |
| Other Gand A | 21.61 | 12.22 | 17.87 | 31.02 |
| Salaries And Wages | 4.55 | 3.64 | - | - |
| Selling And Marketing Expense | 8.44 | 11.99 | 37.09 | 61.40 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Beta Bionics, Inc.this co. | BBNX | $619M | -8.46 | 2.15 | -25.5% | -8.64 |
| Aclaris Therapeutics, Inc. | ACRS | $658M | -10.13 | 6.38 | -63.0% | - |
| Castle Biosciences, Inc. | CSTL | $655M | -27.12 | 1.39 | -5.1% | 50.72 |
| First Tracks Biotherapeutics, Inc. | TRAX | $635M | -3.88 | 1.62 | -41.8% | -2.95 |
| Prime Medicine, Inc. | PRME | $627M |
| -3.12 |
| 5.19 |
| -166.4% |
| -3.38 |
| Gyre Therapeutics, Inc. | GYRE | $601M | 119.48 | 5.66 | 4.7% | 40.29 |
| Phreesia, Inc. | PHR | $599M | 259.74 | 1.78 | 0.7% | 21.30 |
| Ginkgo Bioworks Holdings, Inc. | DNA | $591M | -1.89 | 1.16 | -61.5% | -3.39 |
| Bioventus Inc. | BVS | $589M | 25.93 | 3.20 | 12.3% | 8.39 |
| Peer Median | - | -2.50 | 2.49 | -23.5% | 8.39 | |
Historically, May has averaged the highest return (+37.4%); Jan the lowest (-54.6%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -54.6%Negative MonthJan 2026: -54.61% | -8.7%Negative MonthFeb 2026: -8.68% | -20.7%Negative MonthMar 2026: -20.67% | +1.8%Neutral MonthApr 2026: +1.80% | +18.8%Positive MonthMay 2026: +18.82% | +29.3%Positive MonthJun 2026: +29.29% | -18.1%Negative MonthJul 2026: -18.12% | +56.0%*Positive MonthAug 2026: +55.96% | — | — | — | — |
| 2025 | — | -11.9%Negative MonthFeb 2025: -11.93% | -41.6%Negative MonthMar 2025: -41.63% | -9.7%Negative MonthApr 2025: -9.72% | +56.0%Positive MonthMay 2025: +56.02% | -15.5%Negative MonthJun 2025: -15.55% | +15.3%Positive MonthJul 2025: +15.32% | +12.2%Positive MonthAug 2025: +12.21% | +5.5%Positive MonthSep 2025: +5.47% | +37.0%Positive MonthOct 2025: +36.99% | +15.1%Positive MonthNov 2025: +15.14% | -2.8%Negative MonthDec 2025: -2.78% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 2 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
